Clinical trials: Diabetic Mellitus
Diabetes, Diabetes Mellitus, Type 2
Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea
This trial is conducted in Asia. This trial aims for evaluating the glycaemic control, measured as glycosylated haemoglobin (Hb1Ac), of once daily insulin detemir as an add-on to oral antidiabetic drug (OAD) in subjects with type…
- Trial name
- NCT00455858
- Testing
- insulin detemir
- Where
- South Korea
- Volunteers
- 87 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
Empagliflozin (Jardiance), a highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), was approved in Europe in May 2014 for the treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic…
- Trial name
- NCT02864914
- Testing
- Empagliflozin, DPP-4 inhibitors
- Where
- United Kingdom
- Volunteers
- 333,580 people
- Sponsor
- Boehringer Ingelheim
Diabetic Neuropathy
A Study to Evaluate the Safety of DA-3030 and to Explore the Efficacy for Diabetic Neuropathic Pain
A multi-centers, placebo-controlled, randomized, double-blinded, pilot clinical trial is designed to evaluate the safety of the DA-3030 injection and to explore the efficacy for Neuropathic pain.
- Trial name
- NCT01820715
- Testing
- 600㎍ of DA-3030 Injection
- Where
- South Korea
- Volunteers
- 31 people
- Sponsor
- Dong-A Pharmaceutical Co., Ltd.
Diabetes Mellitus, Obesity
An Ascending Multi-Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers
The purpose of this study is to evaluate the safety and tolerance of multiple intravenous (through a vein) doses of trodusquemine (MSI-1436) in obese or overweight, type 2 diabetics.
- Trial name
- NCT00806338
- Testing
- Trodusquemine (MSI-1436)
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Genaera Corporation
Pressure Ulcer, Diabetic Foot Ulcer
An Open, Non-comparative, Multicenter Investigation to Evaluate the Safety and Performance of Exufiber Ag+, a Gelling Fiber Silver Dressing, When Used in Medium to High Exuding Chronic Wounds
An open, non-comparative, multicenter investigation to evaluate the safety and performance of Exufiber Ag+, a gelling fiber silver dressing, when used in medium to high exuding chronic wounds
- Conditions
- Pressure Ulcer, Diabetic Foot Ulcer, Venous Leg Ulcer
- Trial name
- NCT05494450
- Testing
- ExufiberAG+
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Molnlycke Health Care AB
Diabetic Neuropathy, Painful
Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy
Pregabalin has proven effective in previous clinical trails in other countries in relieving neuropathic pain associated with postherpetic neuralgia and painful diabetic neuropathy.
- Trial name
- NCT01332149
- Testing
- Pregabalin
- Where
- 30 sites in China
- Volunteers
- 626 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Ulcer Healing, Diabetic Foot Ulcer
Evaluating The Efficacy Of A Keratin Graft In Treating Non-Healing Diabetic Foot Ulcers
The goal of this clinical pilot is to collect patient outcome data on a commercially available, keratin-based skin substitute matrix: ProgenaMatrix®.
- Trial name
- NCT05797285
- Testing
- human keratin graft
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- ProgenaCare Global, LLC
Diabetic Foot Ulcer
A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-301 Clinical Trial
This is a follow-up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial (ALLO-ASC-DFU-301) for 24 months
- Trial name
- NCT04590703
- Testing
- ALLO-ASC-DFU, Vehicle sheet
- Where
- 8 sites in South Korea
- Volunteers
- 73 people
- Sponsor
- Anterogen Co., Ltd.
Diabetic Kidney Disease, Proteinuria
An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
This study aims to observe changes in various indicators of renal function, such as proteinuria at different time points: short-term (Week 8), 6 months (Week 26), and a year (Week 52), in patients with DKD and hypertension, who…
- Conditions
- Diabetic Kidney Disease, Proteinuria, Hypertension,Essential
- Trial name
- FINALE (NCT05086549)
- Where
- South Korea
- Volunteers
- 360 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetic Foot Ulcer (DFU), Diabetic Symmetrical Polyneuropathy
Comparative Study of Combination Treatment of Bionerv E+ Versus Vitamin B Complex in Treatment of Diabetic Polyneuropathy in Type 2 Diabetic Patients and Its Effect on Wound Healing
Diabetic symmetrical polyneuropathy (DSPN) is a common complication of diabetes that affects the nerves, especially in the legs and feet. It can cause pain, numbness, tingling, weakness, and loss of sensation.
- Trial name
- NCT07877948
- Testing
- Alpha-Lipoic Acid, Vitamin B1, Vitamin B6, Vitamin B12, Vitamin E, Vitamin B1, Vitamin B6, Vitamin B12
- Where
- Malaysia
- Volunteers
- 100 people
- Sponsor
- BREGO Life Sciences
Type 2 Diabetes Mellitus
Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
To evaluate the similarity of the efficacy and safety of semaglutide injection (HD1916) vs. Ozempic® in patients with type 2 diabetes mellitus (T2DM) with poor blood glucose control after metformin treatment.
- Trial name
- NCT06161844
- Testing
- semaglutide injection (HD1916), Ozempic®
- Where
- China
- Volunteers
- 506 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Diabetes
Feasibility Study of a Novel Subcutaneous Continuous Glucose Monitoring System in Diabetics
Mono-centre, open label (unblinded). 8 patients + 2 potential replacements. Duration up to 9 weeks: up to 6 weeks screening (42 days), 2 weeks of treatment (14 days, depending on sensor functionality) and 1 week of follow up (7…
- Trial name
- FiberSense (NCT06867965)
- Testing
- BellySense
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- EyeSense GmbH
Diabetic Foot Ulcers
TITLE: An Open, Non-comparative, Multi-centre Post Marketing Clinical Follow-up (PMCF) Investigation to Evaluate Performance and Safety on Diabetic Foot Ulcer, DFU, When Using Mepilex Transfer Ag as Intended
An open, non-comparative, multi-centre post marketing clinical follow-up, PMCF, investigation to evaluate performance and safety on diabetic foot ulcer, dfu, when using mepilex transfer Ag as intended.
- Trial name
- MxT Ag 05 (NCT01964521)
- Testing
- Mepilex Transfer Ag
- Where
- 2 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- Molnlycke Health Care AB
Painful Diabetic Neuropathy
Feasibility of Self-treatment of Painful Diabetic Neuropathy Using Electrical Vasomotor Nerve Stimulation
Electrical stimulation with EVNS (Electrical Vasomotor Neuro Stimulation), a methodology used by a specific group of neurostimulators known under various names, has proven its benefit in Painful Diabetic Neuropathy (PDN).
- Trial name
- HOME-EVNS (NCT06524284)
- Testing
- Releaf
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Neurecon BV
Diabetic Complications
Prontosan Versus Saline in the Cleansing of Chronic Leg Ulcers in Diabetic Patients
This is a randomized controlled double blinded study involving two (2) investigational sites in the United States. All subjects (n=40) will receive either Prontosan Wound Irrigation Solution and Gel treatment or standard of care…
- Trial name
- NCT01554644
- Testing
- Prontosan, Saline
- Where
- 2 sites in United States
- Sponsor
- B. Braun Medical Inc.
Painful Diabetic Neuropathy
Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy
The purpose of this study is to determine whether ARC-4558 is effective in managing pain associated with painful diabetic neuropathy.
- Trial name
- NCT00695565
- Testing
- Clonidine Topical Gel (ARC-4558)
- Where
- 16 sites in United States
- Volunteers
- 180 people
- Sponsor
- Arcion Therapeutics Inc
Pressure Ulcer, Diabetic Foot Ulcer
Efficacy of Wound Dressings With Copper Oxide
Thirty patients of 18-85 years of age, with 2-30 cm2 pressure ulcers or post-op wounds, will be recruited and treated with either wound dressing containing silver or wound dressings containing copper oxide microparticles.
- Trial name
- NCT04634838
- Testing
- MedCu Antibacterial Wound Dressings with Copper Oxide
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- MedCu Technologies Ltd.
Diabetic Foot Ulcer, Foot Ulcer
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
This Phase 3 study is a randomized, double-blind, vehicle-controlled, multiple-center, parallel study to evaluate efficacy and safety of ENERGI-F703 GEL compared with vehicle control in subjects with Wagner Grade 1 to Grade 2…
- Conditions
- Diabetic Foot Ulcer, Foot Ulcer, Diabetes Mellitus, Wound
- Trial name
- NCT05930210
- Testing
- ENERGI-F703 GEL, ENERGI-F703 matched vehicle
- Where
- 24 sites in United States, Taiwan
- Volunteers
- 230 people
- Sponsor
- Energenesis Biomedical Co., Ltd.
Diabetes Mellitus, Type 2
Closed Loop Glucose Control in Patients With Type 2 Diabetes
This is a proof of concept safety study of an artificial intelligence based closed loop glucose control system designed for use in the intensive care unit setting.
- Trial name
- NCT05386849
- Testing
- FUSION closed loop glucose control system
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Ideal Medical Technologies
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes.
- Trial name
- COMBINE 2 (NCT05259033)
- Testing
- IcoSema, Semaglutide 1 mg
- Where
- 193 sites in United States, Brazil and 13 more
- Volunteers
- 683 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.